client protein

client protein

A term of art for a protein which is manipulated or processed, as in the folding of a client protein by a chaperone.
Mentioned in ?
References in periodicals archive ?
Also a target protein, the glucocorticoid receptor (GR) protein, will be introduced to observe how the behaviour of each domain changes upon binding a client protein.
By blocking the activity of Hsp90, geldanamycin analogs lead to disruption of the Hsp90-client protein complexes and client protein degradation.
By blocking the activity of Hsp90, Kosan's geldanamycin analogs lead to the disruption of the Hsp90-client protein complexes and the degradation of the client proteins.
By blocking the activity of Hsp90, Kosan's geldanamycin analogs disrupt the Hsp90-client protein complexes, leading to the degradation of the client proteins.
Several mTOR signaling pathway components such as mTOR, AKT and LKB1 are HSP90 client proteins.
Many cancers result from specific mutations in such client proteins; Hsp90 enables those cancers' survival by maintaining the function of their mutated client proteins.
These client proteins include a "who's who" list of cancer-relevant targets such as mutated p53, Bcr-Abl, Raf-1, ErbB2 and other kinases, as well as steroid hormone receptors.
In preclinical studies, inhibiting Hsp90 causes the degradation of multiple client proteins and leads to cancer cell death.
The bead-based multiplex immunoassay enables measurement of HSP client proteins (Akt and Akt phosphor-Ser473) and HSPs (Hsp27 phospho Ser15, Hsp27 phospho-Ser82, Hsp40, Hsp60, Hsp70 and Hsp90 alpha) in cell lysates.
NXD30001 and its analogs efficiently inhibit cell proliferation and deplete multiple Hsp90 client proteins such as Her2, Akt, c-Raf, Cdk4, and Cyclin D1 in Her2-overexpressing breast and other cancer cell lines at low nanomolar concentrations.
NXD30001 and its analogs efficiently inhibit cell proliferation and deplete multiple Hsp90 client proteins such as Her2, Akt, c-Raf, Cdk4, and Cyclin D1 in Her2- overexpressing breast and other cancer cell lines at low nanomolar concentrations.